MDxHealth SA (NASDAQ:MDXH) Short Interest Update

MDxHealth SA (NASDAQ:MDXH) was the target of a significant decline in short interest in January. As of January 15th, there was short interest totaling 25,720 shares, a decline of 34.8% from the December 31st total of 39,441 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily volume of 148,347 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily volume of 148,347 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.1% of the company’s stock are sold short.

MDxHealth Trading Down 1.7%

Shares of NASDAQ:MDXH traded down $0.06 on Friday, reaching $3.50. 101,670 shares of the company’s stock were exchanged, compared to its average volume of 145,256. MDxHealth has a twelve month low of $1.35 and a twelve month high of $5.33. The company has a fifty day moving average of $3.51 and a 200-day moving average of $3.61. The company has a market capitalization of $165.52 million, a price-to-earnings ratio of -5.47 and a beta of 1.62.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 30.50%.The company had revenue of $27.43 million during the quarter, compared to the consensus estimate of $24.11 million. As a group, equities research analysts forecast that MDxHealth will post -1.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on MDXH shares. Lake Street Capital raised their price target on MDxHealth from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a research note on Monday, December 29th. BTIG Research reaffirmed a “buy” rating and set a $7.00 price target on shares of MDxHealth in a research report on Tuesday, December 23rd. Finally, TD Cowen increased their price target on shares of MDxHealth from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $7.75.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. GSA Capital Partners LLP acquired a new stake in shares of MDxHealth during the third quarter valued at about $48,000. Lido Advisors LLC acquired a new stake in MDxHealth during the 3rd quarter worth approximately $48,000. Jefferies Financial Group Inc. bought a new stake in MDxHealth during the 3rd quarter worth approximately $53,000. Hudson Bay Capital Management LP acquired a new position in MDxHealth in the 3rd quarter valued at approximately $70,000. Finally, Bank of America Corp DE lifted its holdings in shares of MDxHealth by 5,164.0% during the third quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock worth $70,000 after purchasing an additional 14,769 shares during the period.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.